Yaqrit Ltd
- Medical device or technology
- Biotech or pharma, therapeutic R&D
Yaqrit is a late clinical-stage advanced liver disease company, with 5 innovative phase 2/3-ready pipeline products that aim to prevent and treat patients with advanced cirrhosis and acute-on-chronic-liver failure (ACLF). A spin out of University College of London (UCL), the core research of the company has been led by Professor Rajiv Jalan and his colleagues, alongside a network of pharmaceutical company partners. Out of over 100 million patients with cirrhosis globally, 10+ million patients are hospitalized with decompensation, around 2 million develop ACLF and over 1 million patients die each year. Yaqrit’s ambition is to change these clinical outcomes and provide a new generation of therapeutics for patients suffering from liver disease.